Jan 23 (Reuters) - Grifols SA ::RIGEL PHARMACEUTICALS ENTERS COLLABORATION AND LICENSE AGREEMENT WITH GRIFOLS, S.A. TO COMMERCIALIZE FOSTAMATINIB IN EUROPE.RIGEL PHARMACEUTICALS - TO RECEIVE AN UPFRONT PAYMENT OF $30 MILLION, WITH POTENTIAL FOR $297.5 MILLION IN TOTAL REGULATORY AND COMMERCIAL MILESTONES.RIGEL PHARMACEUTICALS INC - GRIFOLS GAINS EXCLUSIVE RIGHTS TO FOSTAMATINIB IN ALL POTENTIAL INDICATIONS IN EUROPE AND TURKEY.RIGEL PHARMACEUTICALS INC - TO RECEIVE STEPPED ROYALTY PAYMENTS REACHING 30% OF NET SALES OF FOSTAMATINIB.RIGEL PHARMACEUTICALS - ANTICIPATES A DECISION FROM EMA'S COMMITTEE ON HUMAN MEDICINAL PRODUCTS BY Q4 OF 2019 AND POTENTIAL EUROPEAN APPROVAL BY 2019 END.
Full Article
Nov 6 (Reuters) - Rigel Pharmaceuticals Inc ::RIGEL ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE.Q3 LOSS PER SHARE $0.14.Q3 EARNINGS PER SHARE VIEW $-0.15 -- THOMSON REUTERS I/B/E/S.
Full Article
March 9 (Reuters) - Rigel Pharmaceuticals Inc ::RIGEL PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UP TO $200 MILLION – SEC FILING.
Full Article
Jan 4 (Reuters) - Rigel Pharmaceuticals Inc ::RIGEL PHARMACEUTICALS - FDA HAS CONFIRMED IT DOES NOT PLAN TO CONVENE ONCOLOGY DRUGS ADVISORY COMMITTEE MEETING TO DISCUSS NDA FOR FOSTAMATINIB.RIGEL PHARMACEUTICALS INC - ACTION DATE FOR FDA TO COMPLETE ITS REVIEW FOR FOSTAMATINIB IS APRIL 17, 2018 UNDER PDUFA.
Full Article
Dec 15 (Reuters) - Rigel Pharmaceuticals Inc ::RIGEL ANNOUNCES DEPARTURE OF CHIEF FINANCIAL OFFICER.RESIGNATION OF RYAN MAYNARD, EXECUTIVE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER, EFFECTIVE DECEMBER 31, 2017.COMPANY HAS INITIATED AN EXTERNAL SEARCH FOR ITS NEXT CHIEF FINANCIAL OFFICER.NELSON CABATUAN, RIGEL'S VICE PRESIDENT, FINANCE WILL SERVE AS COMPANY'S INTERIM PRINCIPAL ACCOUNTING OFFICER.
Full Article
Nov 7 (Reuters) - Rigel Pharmaceuticals Inc :Rigel announces third quarter 2017 financial results and provides company update.Q3 loss per share $0.14.
Full Article
Oct 3 (Reuters) - Rigel Pharmaceuticals Inc :Rigel announces proposed public offering of common stock.Rigel Pharmaceuticals Inc - intends to offer and sell up to $40 million of shares of its common stock in an underwritten public offering.Rigel Pharmaceuticals Inc - proceeds to be used to fund research and development activities, commercial preparation.
Full Article
Aug 1 (Reuters) - Rigel Pharmaceuticals Inc :Rigel announces second quarter 2017 financial results and provides company update.Q2 loss per share $0.16.Q2 earnings per share view $-0.15 -- Thomson Reuters I/B/E/S.
Full Article
May 5 (Reuters) - Aclaris Therapeutics Inc : :Aclaris Therapeutics completes phase 1 clinical trial of ati-50001 for the treatment of alopecia universalis and alopecia totalis.In trial, treatment with ati-50001 capsules was well tolerated, with a safety profile similar to placebo.No clinically significant laboratory abnormalities were observed.Aclaris Therapeutics - data consistent with results from earlier phase 1 clinical trial conducted by rigel pharma in which study drug was well tolerated at all doses.Aclaris Therapeutics - plans to initiate phase 2 dose ranging trial with ati-50001 for treatment of alopecia totalis, alopecia universalis in second half of 2017.Aclaris Therapeutics - plans to submit an investigational new drug application (ind) for ati-50002 for treatment of patchy alopecia areata in mid-2017.Plans to initiate phase 2 trial of ati-50002 for treatment of vitiligo in second half of 2017.Aclaris Therapeutics Inc - plans to initiate a phase 2 dose ranging trial of ati-50002 for treatment of patchy alopecia areata in second half of 2017.
Full Article
May 2 (Reuters) - Rigel Pharmaceuticals Inc :Rigel announces first quarter 2017 financial results and provides company update.Q1 loss per share $0.13.Q1 earnings per share view $-0.12 -- Thomson Reuters I/B/E/S.Rigel Pharmaceuticals Inc - As of March 31, 2017, Rigel had cash, cash equivalents and short-term investments of $98.1 million.Rigel Pharmaceuticals-Expects cash, cash equivalents and short-term investments to be sufficient to support current and projected funding requirements.Rigel Pharmaceuticals - Is selecting a molecule from its irak program for preclinical development.Rigel Pharmaceuticals-Expected that irak program development will include clinical evaluation in immunology areas, such as for lupus, gout and/or psoriasis.Rigel Pharmaceuticals Inc qtrly contract revenues from collaborations $3.6 million versus $5.0 million.
Full Article
Earnings vs. 
Estimates